Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Video

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Filip Janku, MD, PhD, discusses the results form a phase 1 study (NCT02571036) of ripretinib (Qinlock), a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

The data that came out of this study demonstrated a higher efficacy than what has previously been reported, according to Janku. When evaluating confirmed responses with stringent criteria, 1 complete response and 5 partial responses were observed, which translates to an overall response rate of approximately 23% in the intent-to-treat population of 26 patients, Janku explains.

There were additionally 2 unconfirmed responses, and with these included, the ORR would be 31%, Janku adds. Even more importantly, the patient responses to ripretinib proved to be durable, with a median duration of response over 9.0 months, and a progression-free survival of 7.3 months, which is the most positive data ever reported for this patient population, Janku concludes. 

Related Videos
Jane L. Meisel, MD, Emory University
Jeffrey Zonder, MD
Jun Gong, MD
John Michael Bryant, MD,
Chandler H. Park, MD, FACP
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center